|
| 36686712 | Expanding the toolbox of metabolically stable lipid prodrug strategies. | Front Pharmacol | 2023 |
| 37878666 | High throughput analysis of B cell dynamics and neutralizing antibody development during immunization with a novel clade C HIV-1 envelope. | PLoS Pathog | 2023 |
| 37553348 | Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques. | Nat Commun | 2023 |
| 36686712 | Expanding the toolbox of metabolically stable lipid prodrug strategies. | Front Pharmacol | 2023 |
| 37553348 | Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques. | Nat Commun | 2023 |
| 37878666 | High throughput analysis of B cell dynamics and neutralizing antibody development during immunization with a novel clade C HIV-1 envelope. | PLoS Pathog | 2023 |
| 35179893 | Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles. | J Med Chem | 2022 |
| 35503780 | A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence. | PLoS Pathog | 2022 |
| 35935987 | V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques. | Front Immunol | 2022 |
| 35867800 | A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques. | Sci Immunol | 2022 |
| 35179893 | Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles. | J Med Chem | 2022 |
| 35503780 | A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence. | PLoS Pathog | 2022 |
| 35935987 | V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques. | Front Immunol | 2022 |
| 35867800 | A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques. | Sci Immunol | 2022 |
| 33463551 | Early T follicular helper cell activity accelerates hepatitis C virus-specific B cell expansion. | J Clin Invest | 2021 |
| 33463551 | Early T follicular helper cell activity accelerates hepatitis C virus-specific B cell expansion. | J Clin Invest | 2021 |
| 33556148 | The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection. | PLoS Pathog | 2021 |
| 34459598 | Ï¿-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties. | J Med Chem | 2021 |
| 34449812 | Increased homeostatic cytokines and stability of HIV-infected memory CD4 T-cells identify individuals with suboptimal CD4 T-cell recovery on-ART. | PLoS Pathog | 2021 |
| 33556148 | The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection. | PLoS Pathog | 2021 |
| 34459598 | Ï¿-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties. | J Med Chem | 2021 |
| 34449812 | Increased homeostatic cytokines and stability of HIV-infected memory CD4 T-cells identify individuals with suboptimal CD4 T-cell recovery on-ART. | PLoS Pathog | 2021 |
| 32393800 | T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. | Nat Med | 2020 |
| 32393800 | T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. | Nat Med | 2020 |
| 30697215 | VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120. | Front Immunol | 2019 |
| 31748228 | Strong T<sub>H</sub>1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy. | Sci Transl Med | 2019 |
| 31589166 | Striking a balance in an antibody network: A roadmap for HIV-1 vaccines. | J Clin Invest | 2019 |
| 30651354 | Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants. | J Virol | 2019 |
| 30697215 | VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120. | Front Immunol | 2019 |
| 31341049 | Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. | J Virol | 2019 |
| 31748228 | Strong T<sub>H</sub>1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy. | Sci Transl Med | 2019 |
| 31589166 | Striking a balance in an antibody network: A roadmap for HIV-1 vaccines. | J Clin Invest | 2019 |
| 31341049 | Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. | J Virol | 2019 |
| 30651354 | Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants. | J Virol | 2019 |
| 27928002 | Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques. | J Virol | 2017 |
| 28649869 | HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights. | AIDS Res Hum Retroviruses | 2017 |
| 28250119 | New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif. | J Virol | 2017 |
| 27928002 | Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques. | J Virol | 2017 |
| 28250119 | New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif. | J Virol | 2017 |
| 28649869 | HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights. | AIDS Res Hum Retroviruses | 2017 |
| 26918160 | Harnessing the protective potential of HIV-1 neutralizing antibodies. | F1000Res | 2016 |
| 26918160 | Harnessing the protective potential of HIV-1 neutralizing antibodies. | F1000Res | 2016 |
| 26499044 | Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy. | Virology | 2016 |
| 27851829 | Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth. | PLoS Pathog | 2016 |
| 27653601 | CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy. | Immunity | 2016 |
| 27716795 | Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein. | PLoS Comput Biol | 2016 |
| 26499044 | Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy. | Virology | 2016 |
| 27851829 | Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth. | PLoS Pathog | 2016 |
| 27716795 | Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein. | PLoS Comput Biol | 2016 |
| 27653601 | CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy. | Immunity | 2016 |